Anti-MUC1 [CD-2] Antibody
![Anti-MUC1 [CD-2] Antibody](https://www.kerafast.com/MediaStorage/Product/Images/Large/2065_2001202001271220640.jpg "Anti-MUC1 [CD-2] Antibody")
This IgG1 kappa antibody was generated against recombinant human MUC1-C cytoplasmic domain (MUC1-CD) and recognizes an epitope (NYGQLDIFP) between amino acids 7 and 15.
Anti-MUC1 (CD-2) is ideal for Immunohistochemistry (IHC) and Immunofluorescence (IF) experiments.
Mucin 1 (MUC1) is aberrantly overexpressed in diverse human carcinomas and certain hematologic malignancies, and is an attractive target for drug development. MUC1 consists of two subunits; the MUC1 C-terminal (MUC1-C) subunit is an oncoprotein and cancer target. The MUC1-C subunit contains an extracellular domain, a transmembrane region, and a cytoplasmic domain. The MUC1-C cytoplasmic domain (CD) has been shown to interact with effectors such as PI3K, NF-kappaB, and Beta-Catenin which have all been linked to transformation. The MUC1-C cytoplasmic domain also contains a CQC motif necessary for dimerization, interaction with effectors, and nuclear localization. Cell-penetrating peptides and small molecules have been designed to block this site, one of which is currently in Phase I clinical evaluation. As vaccines and drugs are well under development against MUC1, antibodies will serve as useful biomarkers to define those patients who express MUC1-C and are thus likely to respond.
From the laboratory of Donald W. Kufe, MD, Dana-Farber Cancer Institute.
Part of The Investigator's Annexe program.
This IgG1 kappa antibody was generated against recombinant human MUC1-C cytoplasmic domain (MUC1-CD) and recognizes an epitope (NYGQLDIFP) between amino acids 7 and 15.
Anti-MUC1 (CD-2) is ideal for Immunohistochemistry (IHC) and Immunofluorescence (IF) experiments.
Mucin 1 (MUC1) is aberrantly overexpressed in diverse human carcinomas and certain hematologic malignancies, and is an attractive target for drug development. MUC1 consists of two subunits; the MUC1 C-terminal (MUC1-C) subunit is an oncoprotein and cancer target. The MUC1-C subunit contains an extracellular domain, a transmembrane region, and a cytoplasmic domain. The MUC1-C cytoplasmic domain (CD) has been shown to interact with effectors such as PI3K, NF-kappaB, and Beta-Catenin which have all been linked to transformation. The MUC1-C cytoplasmic domain also contains a CQC motif necessary for dimerization, interaction with effectors, and nuclear localization. Cell-penetrating peptides and small molecules have been designed to block this site, one of which is currently in Phase I clinical evaluation. As vaccines and drugs are well under development against MUC1, antibodies will serve as useful biomarkers to define those patients who express MUC1-C and are thus likely to respond.
From the laboratory of Donald W. Kufe, MD, Dana-Farber Cancer Institute.
Part of The Investigator's Annexe program.
| Product Type: | Antibody |
| Antigen: | Muc1-Cytoplasmic Domain (MUC1-CD) |
| Accession ID: | P15941 |
| Isotype: | IgG1 kappa |
| Clonality: | Monoclonal |
| Clone Name: | CD-2 |
| Reactivity: | Human |
| Immunogen: | Purified protein |
| Species Immunized: | Mouse |
| Epitope: | NYGQLDIFP |
| Purification Method: | Affinity chromatography |
| Method Used to Determine Concentration: | Nanodrop |
| Buffer: | PBS, 0.05% (w/v) Sodium Azide |
| Tested Applications: | IF, IHC |
| Concentration: | 1mg/mL |
| Storage: | 4C (working) -20C or -80C (stock) |
| Shipped: | Cold packs |
Immunohistochemistry using Anti-MUC1 (CD2)
Breast carcinoma tumor specimens from three separate patients (A-C) were stained for MUC1 using Anti-MUC1 (CD-1) mAb. Kufe, D.W., unpublished data.
IHC Protocol for anti-MUC1-CD antibody (clone CD-2)
Incubate slides in a 60C oven to melt the paraffin for 15 min, transfer them to xylene substitute for 10 min and then deparaffinize (2 rounds of xylene, 100% ethanol, 95% ethanol, 75% ethanol until water).
Antigen retrieval (HIER: Heat Induced Epitope Retrieval) is done using a Biocare Decloaker (pressure cooker). Place the slide rack in Diva Decloaker solution (Biocare) pH 6.0, heat at 100C for 35 min and then cool to 85C for 10 min. Transfer the slides to DI water and then stain.
Staining
(All reagents are from Biocare Medical). Staining is done using the Intellipath Auto Stainer (automatic stainer).
- Block: Peroxidase 1 (10 min)
- Wash with TBS+tween
- Block: Background Sniper
- Wash with TBS+tween
- ab: CD-2 1:100 for 2 hrs
- Wash with TBS+tween
- Secondary: Mouse Secondary Reagent (15 min)
- Wash with TBS+tween
- Secondary: Universal HRP Reagent (15 min)
- Wash with TBS+tween
- Chromagen (mixed online): DAB (5 min)
- Wash with DI Water x 2
- Counterstain: Hematoxylin (3 min)
- Wash with TBS+tween
- Slides are ready to be dehydrated and mounted.
- Kufe, DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene, 1-9 (2012).Kufe, DW. Mucins in cancer: function,prognosis and therapy. Nat Rev Cancer. 9(12):874-85 (2009).
- David JM, Hamilton DH, Palena C. MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury mediated epithelial-mesenchymal transition. Oncoimmunology. 2016 Jan 6;5(4):e1117738. PubMed PMID: 27141403; PubMed Central PMCID: PMC4839328. View Article
If you publish research with this product, please let us know so we can cite your paper.
